Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries

Coronary Artery Disease

Volumn 19, Issue 8, 2008, Pages 635-643

  Hemetsberger, Rayyan ^a   Farhan, Serdar ^b   Strehblow, Christoph ^a   Sperker, Wolfgang ^a   Pavo, Imre ^a   Petrasi, Zsolt ^c   Hemetsberger, Hani ^a   Posa, Aniko ^a   Huber, Kurt ^b   Glogar, Dietmar ^a   Gyöngyösi, Mariann ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

Clopidogrel; Dual antiplatelet therapy; In stent restenosis; Neointimal hyperplasia; Stent

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; CYTOKINE; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ARTERY; CORONARY STENT; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; FIBRIN DEPOSITION; IN-STENT RESTENOSIS; INFLAMMATION; LOADING DRUG DOSE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ASPIRIN; CELL PROLIFERATION; COLLAGEN; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY VESSELS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRIN; HYPERPLASIA; INFLAMMATION MEDIATORS; METALS; P-SELECTIN; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; STENTS; SWINE; TICLOPIDINE; TIME FACTORS; TUNICA INTIMA;

EID: 56849131210     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32831425ed     Document Type: Article

References (33)

1. Juergens CP, Wong AM, Leung DYC, Lowe HC, Lo S, Fernandes C, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after stent implantation. Am Heart J 2004; 147:e15.
2. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348:1329-1339.
3. Quinn MJ, Fitzgerald DJ. Ticlopidine and Clopidogrel. Circulation 1999; 100:1667-1672.
4. Müller C, Butter HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101:590-593.
5. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102:624-629.
6. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. (TOPPS) Circulation 2001; 104:539-543.
7. Müller C, Roskamm H, Neumann FJ, Hunziker P, Marsch S, Perruchoud A, Bütter HJ. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 2003; 41:969-973.
8. Wolak A, Amit G, Cafri C, Gilutz H, Ilia R, Zahger D. Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. Int J Cardiol 2005; 103:293-297.
9. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9-14.
10. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug- eluting stents. J Am Coll Cardiol 2004; 44:1373-1385.
11. Indolfi C, Mongiardo A, Curcio A, Torella D. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 2003; 13:142-148.
12. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999; 10:499-506.
13. Welt FGP, Campbell R. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
14. Gyöngyösi M, Strehblow C, Sperker W, Hevesi A, Garamvölgyi R, Petrasi Z, et al. Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 h. Thromb Haemost 2006; 96:202-209.
15. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19:267-274.
16. Schwartz RS. Edelman ER for the Consensus Committee: drug-eluting stents in preclinical studies. Recommended evaluation from a Consensus Group. Circulation 2002; 106:1867-1873.
17. Pessanha BS, Potter K, Kolodgie FD, Farb A, Kutys R, Mont EK, et al. Characterization of intimal changes in coronary artery specimens with MR microscopy. Radiology 2006; 241:107-115.
18. Samara W, Gurbel P. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis 2003; 14:65-79.
19. Clark RA, Klebanoff SJ. Neutrophil-platelet interaction mediated by myeloperoxidase and hydrogen peroxide. J Immunol 1980; 124:399-405.
20. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001; 104:2228-2235.
21. Saadi BS, Holzknecht RA, Patte C, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182:1807-1814.
22. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001; 15:2337-2344.
23. Wexberg P, Jordanova N, Strehblow C, Syeda B, Meyer B, Charvat S, et al. Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation. Thromb Haemost 2008; 99:739-748.
24. Dunzendorfer S, Reinisch CM, Kaneider NC, Pechlander CH, Wiedermann CHJ. Inhibition of plasma-dependent monocyte chemokinesis and cytokine-triggered endothelial activation for neutrophil transmigration by administration of clopidogrel in man. Acta Med Austriaca 2002; 29:100-106.
25. Perneby C, Wallen NH, Hofman-Bang C, Tornvall P, Ivert T, Li N, et al. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. Thromb Haemost 2007; 98:1316-1322.
26. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005; 5:399-408.
27. Li M, Zhang Y, Ren H, Zhang Y, Zhu X. Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 2007; 194:348-356.
28. Akbulut M, Ozbay Y, Karaca I, Ilkay E, Gundogdu O, Arslan N. The effect of long-term Clopidogrel use on neointimal formation after percutaneous coronary intervention. Coron Artery Dis 2004; 15:347-352.
29. Waehre T, Damas JK, Pedersen TM, Gullestad L, Yndestad A, Andreassen AK. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006; 4:2140-2147.
30. Rand ML, Leung R, Packham MA. Platelet function assays. Trans Apher Sci 2003; 28:307-317.
31. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27:2420-2425.
32. Breddin HK. Can platelet aggregometry be standardized?. Platelets 2005; 16:151-158.
33. Munster AM, Olsen AK, Bladbjerg EM. Usefulness of human coagulation and fibrinolysis assays in domestic pigs. Comp Med 2002; 52:39-43.